{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:12:04Z","timestamp":1778663524898,"version":"3.51.4"},"reference-count":0,"publisher":"Czech Society of Ophthalmology of the CzMA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cesk Slov Oftalmol"],"published-print":{"date-parts":[[2026,3,23]]},"abstract":"<jats:p>Aims: To evaluate retrospectively the clinical characteristics and therapeutic outcomes in eyes with secondary vasoproliferative retinal tumors (VPRT) at a tertiary center in Turkey.\n\nMaterial and Methods: Patients diagnosed with secondary VPRT between 2005 and 2025 with a follow-up of 6 months or more were included. 24 eyes of 21 patients were evaluated. Their charts and multimodal imaging features were analyzed, and treatments noted.\n\nResults: Mean age was 26.1 years (6\u201357). Mean follow-up was 61.1 months (6\u2013151). Baseline BCVA was 0.77 LogMAR (0.00\u20132.30). VPRT was linked to non-infectious uveitis in 12 patients, retinitis pigmentosa in 5 patients, X-linked Juvenile Retinoschisis, Coats\u2019 disease, retinal dystrophy and retinopathy of prematurity in 1 patient each. The inferotemporal quadrant was the most common site (66.7%). Treatments included dexamethasone implant, transscleral cryotherapy, systemic immunosuppressive therapy, laser photocoagulation, CyberKnife, intravitreal anti-VEGF, vitreoretinal surgery, photodynamic therapy, intravitreal triamcinolone acetonide and enucleation. At baseline, 15 eyes had macular intraretinal fluid. At the final visit, dry macula was achieved in 9 of 15 eyes. Mean final BCVA was 1.01 LogMAR (0.00\u20133.00). Two eyes deteriorated to no light perception. One was enucleated.\n\nConclusion: This largest cohort of patients from Turkey with secondary VPRT reflects the diverse underlying etiologic associations and heterogeneous clinical manifestations at a tertiary center. Various therapeutic techniques were required to cope with this difficult-to-treat, challenging disease entity.<\/jats:p>","DOI":"10.31348\/2026\/18","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:24:46Z","timestamp":1778505886000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Features and Therapeutic Alternatives in Eyes with Secondary Vasoproliferative Tumors: A Single-Center Turkish Perspective"],"prefix":"10.31348","author":[{"given":"Gorkem","family":"Polat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Karti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziya","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Tunc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remzi","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Osman","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2026,3,23]]},"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:32:07Z","timestamp":1778661127000},"score":1,"resource":{"primary":{"URL":"https:\/\/cs-ophthalmology.cz\/en\/journal\/articles\/468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.31348\/2026\/18","relation":{},"ISSN":["1211-9059","1805-4447"],"issn-type":[{"value":"1211-9059","type":"print"},{"value":"1805-4447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}